The anti-PCSK9 monoclonal antibodies evolocumab and alirocumab represent a new group of non-statin hypolipidemic medications targeted at achieving significant reductions in LDLc, specifically in patients with high cardiovascular risk who do not attain the currently recommended LDLc goals, despite lifestyle changes and a maximum tolerated dose of statins in monotherapy or combined with ezetimibe. They are also directed to patients with intolerance, or a contraindication, to the use of statins, but who also have a high risk of cardiovascular events. The clinical evidence shows that the PCSK9 inhibitors are effective and safe medications, and that they reduce cardiovascular events.
Alonso, R., & Cuevas, A. (2017). Indicaciones para el uso de los inhibidores de la PCSK9. Revista Colombiana de Cardiologia, 24, 19–24. https://doi.org/10.1016/j.rccar.2017.08.020